

Cutaquig SCIG Therapy Patient Referral and Prescription

Sheet Return Signed RX via Fax to 207.810.2372
--

То:		From:				Phone:				
Intake phone: 877.373.1523		Fax:		Numbe	Number of Pages (Including Cover			er):		
Date:	DOB:	1	Aller	gies:			-			
Patient Name:	Height: Weight:					t:				
□ Begin Cutaquig SCIG per KabaFusion protocol formonths □ Begin Cutaquiggrams SCIG everyformonths □ KabaFusion to provide infusion pump needle administration sets (A4221) □ KabaFusion to provide infusion supplies for infusion pump (K0552) □ KabaFusion to provide mechanical ambulatory infusion pump (E0779) □ Infusion RN home visit prior to therapy start to assess patient and home environment, educate patient about SCIG therapy. □ Infusion RN visits x 3 and PRN to educate patient to self administer Cutaquig infusion □ KabaFusion to provide all professional services related to infusion										
Diagnosis:									ICD-10	
Common Variable Immunodeficiency with Predominant Immunoregulatory T-Cell Disorders									D83.1	
Wiskott-Aldrich Syndrome									D82.0	
Combined Immunodeficiency, Unspecified									D81.9	
Severe Combined Immunodeficiency [SCID] with Low T- and B- Cell Numbers									D81.1	
Severe combined Immunodeficiency [SCID] with Low or Normal B-Cell Numbers									D81.2	
Selective deficiency of Immunoglobulin A IgA]									D80.2	
Selective deficiency of Immunoglobulin M [IgM]									D80.4	
Selective deficiency of Immunoglobulin G [IgG] Subclasses									D80.3	
Hereditary Hypogammaglobulinemia									D80.0	
Immunodeficiency with Increased IgM									D80.5	
Other Common Variable Immunodeficiencies									D83.8	
Common Variable Immunodeficiency, Unspecified									D83.9	
Other:										
Premedication Orders: Refill x 1Year Per KabaFusion recommendat ACETAMINOPHEN 650 MG (32		DIPHENHYDRAMINE 25 MG orally PRE-SCIG Other: Epinephrine 0.3mg 2-Pak Auto-Injector None								
Prescriber Signature:Date										
Print Prescriber Name:NPI#										
 Please fax the following information: Immunoglobulin order – include dose, route of administration, frequency, duration, and any pre-medications OR use prescription order section above Patient demographics – include insurance information. We will obtain authorization unless the insurance dictates otherwise H & P OR progress note(s) describing diagnosis and clinical status Labs – BUN/Creatinine (preferred within last 90 days), Immunoglobulin Panel 										
CONFIDENTIALITY NOTICE The following includes confidential, proprietary information that is the sole exclusive property of KabaFusion Holdings, LLC. No rights in, relating to, or derived from such information are assigned or otherwise transferred by this document, and the recipient of such information is subject to obligations of secrecy to and for the benefit of KabaFusion Holdings, LLC. No rights in, relating to, or derived from such information is strictly prohibited. This message, together with any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination, or copying of this message, or any attachment, is strictly prohibited. If you have received this message in error, please notify the original sender immediately by telephone or by return fax and shred this document along with any other documents. Thank you.										
KabaFusion Infusion Pharmacy 12 Northbrook Drive Suite 1 Falmouth, ME 04105 Phone: 877.373.1523 Fax: 207.810.2372 <u>www.kabafusion.com</u>										